Transaction DateRecipientSharesTypePriceValue
2nd November 2020Floyd F. Petersen500Open or private sale$19.84$9,919.95
1st October 2020Floyd F. Petersen500Open or private sale$18.89$9,445.80
1st September 2020Floyd F. Petersen500Open or private sale$19.90$9,948.05
14th August 2020William J Peters5,512Open or private sale$20.36$112,223.22
14th August 2020David Maris1,000Open or private purchase$20.26$20,260.00
11th August 2020Richard K Prins6,000Open or private sale$20.33$121,976.40
3rd August 2020Floyd F. Petersen500Open or private sale$20.62$10,307.75
21st July 2020Yakob Liawatidewi5,978Open or private sale$21.22$126,837.02
21st July 2020Yakob Liawatidewi5,978Exercise of derivative$11.33$67,730.74
20th July 2020Yakob Liawatidewi4,186Open or private sale$21.03$88,046.65
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.


Ticker: AMPH
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
SEC Central Index Key (CIK): 1297184
Employees: 2078
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $87 M (18%)
Inventory, Net: $105 M (0%)
Assets, Current: $267 M (4%)
Property, Plant and Equipment, Net: $238 M (0%)
Other Assets, Noncurrent: $13 M (13%)
Assets: $600 M (2%)
Accounts Payable, Current: $22 M (-13%)
Accrued Liabilities, Current: $54 M (3%)
Liabilities, Current: $93 M (3%)
Other Liabilities, Noncurrent: $11 M (16%)
Liabilities: $158 M (-1%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $54 M (3%)
Retained Earnings (Accumulated Deficit): $120 M (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $5 M (10%)
Treasury Stock, Value: $1 M (16%)
Stockholders' Equity (Parent): $398 M (4%)
Liabilities and Equity: $600 M (2%)
Gross Margin: $33 M (0%)
Research and Development: $16 M (-48%)
Sales and Marketing: $4 M (-45%)
General and Administrative Expenses: $16 M (-40%)
Operating Income/Loss: $3 M (0%)
Other Income, net: $1 M (0%)
Provision for income taxes: $75 Th (0%)